Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
May 22, 2024 11:15 ET
|
Upstream Bio, Inc.
Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
May 15, 2024 07:00 ET
|
Upstream Bio, Inc.
Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference